Ceritinib

Introduction Overview

Generic Name

ceritinib

Brand Name

Zykadia

Dosage Form

Oral capsule

Drug Class

Multikinase inhibitors

Pharmacokinetics

Absorption:
Ceritinib is administered orally and is best absorbed when taken with food, which significantly increases its bioavailability. Pharmacokinetic studies demonstrate that the presence of a high-fat meal increases plasma concentrations of ceritinib substantially compared to administration in the fasted state. The peak plasma concentration (Cmax) is typically reached within 4 to 6 hours post-dose under fed conditions. The absolute bioavailability of ceritinib has not been fully characterized due to its poor solubility and extensive first-pass metabolism; however, food markedly improves its absorption. Various patient factors including gastrointestinal motility, pH, and co-administration of gastric acid-reducing agents can influence absorption, requiring attention in clinical management.

Distribution:
Ceritinib is extensively distributed throughout the body with a high volume of distribution indicative of significant tissue penetration, which is crucial for targeting metastatic cancer cells in various organs. It is highly bound to plasma proteins, primarily albumin, with protein binding estimated around 97%. This high protein binding affects its distribution dynamics and potential for interactions with other highly bound drugs. Studies demonstrate that ceritinib can cross biological membranes effectively, possibly contributing to its efficacy in treating metastatic sites including the central nervous system. Nonetheless, its penetration across the blood-brain barrier is considered limited but sufficient for therapeutic activity against brain metastases commonly associated with non-small cell lung cancer (NSCLC).

Metabolism:
Ceritinib undergoes extensive hepatic metabolism primarily via the cytochrome P450 system, predominantly CYP3A4/5 isoforms. The parent drug is metabolized into multiple metabolites, with some retaining pharmacologic activity but generally at lower potency compared to the parent compound. The metabolic pathway includes oxidative and possibly conjugative processes, resulting in inactive or less active metabolites excreted mainly via feces. Co-administration with strong CYP3A inhibitors or inducers significantly affects ceritinib plasma concentrations, necessitating careful management to avoid toxicity or therapeutic failure. Genetic polymorphisms in CYP enzymes may also influence metabolism and patient response.

Elimination:
The elimination of ceritinib occurs primarily through fecal excretion, with approximately 90% of the administered dose recovered in feces, largely as metabolites, reflecting biliary excretion as the major route. Renal excretion plays a minimal role in elimination (<1%), indicating that dose adjustments in renal impairment are generally not required. The terminal elimination half-life of ceritinib is approximately 31 hours, supporting once-daily dosing. The steady-state plasma concentrations are typically achieved within 15 days of repeated dosing. Drug clearance may be variably affected by hepatic impairment, and close monitoring or dose adjustments may be needed in patients with compromised liver function, as accumulation could increase the risk of adverse effects.

Dosage Forms

Available Dosage Forms:
Zykadia is available as oral capsules designed for systemic therapy in oncology. The capsules come in a strength of 150 mg each.

Dosages for Adults and Adolescents:
The standard adult dosing regimen for treating anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) is a total daily dose of 750 mg administered orally once daily. This dose is typically given on an empty stomach or under specific dietary conditions to optimize absorption, although recent guidelines recommend administration with food for improved bioavailability. The treatment continues until disease progression or unacceptable toxicity occurs. If a dose is missed and the next dose is more than 12 hours away, it should be taken as soon as possible; if less than 12 hours, it should be skipped to avoid doubling the dose.

Specific Patient Populations:
Dose adjustments or discontinuation may be necessary in patients unable to tolerate doses as low as 300 mg daily. In patients with hepatic impairment, careful monitoring is required due to altered metabolism and potential drug accumulation. Renal impairment generally does not require dose adjustment given the minimal renal elimination of ceritinib. Pediatric use has not been established definitively; therefore, use is generally confined to adults and adolescents under specialist supervision. In pregnant or breastfeeding women, Zykadia is contraindicated due to its potential teratogenic effects. Special populations include patients with electrolyte imbalances, cardiac conduction abnormalities, or pancreatitis history, necessitating thorough pre-treatment evaluations and ongoing monitoring.

Mechanism Of Action

Ceritinib, the active ingredient in Zykadia, functions primarily as a selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase, which plays a pivotal role in the pathogenesis of certain lung cancers. The ALK fusion gene leads to constitutive activation of the kinase, promoting uncontrolled cellular proliferation and survival. Ceritinib binds competitively to the ATP-binding site of the ALK enzyme, inhibiting its kinase activity and thereby blocking downstream signaling pathways that drive tumor growth.

At the cellular level, inhibition of ALK phosphorylation interrupts multiple critical signaling cascades including the PI3K/AKT, MAPK/ERK, and JAK/STAT pathways. This disruption results in cell cycle arrest, apoptosis induction, and inhibition of angiogenesis within ALK-positive tumor cells. Ceritinib demonstrates higher potency and efficacy compared to first-generation ALK inhibitors such as crizotinib, particularly against resistance mutations within the ALK gene.

Biochemically, ceritinib’s interaction with other receptor tyrosine kinases, including insulin-like growth factor receptor (IGF-1R) and ROS1, contributes to its broader antitumor activity profile. However, its primary clinical efficacy is attributed to potent inhibition of ALK. Clinical trials have validated its effectiveness in patients with advanced or metastatic non-small cell lung cancer harboring ALK rearrangements, especially those who have progressed on or are intolerant to crizotinib therapy.

Research evidence also demonstrates ceritinib's ability to cross the blood-brain barrier to some extent, providing therapeutic benefit against central nervous system metastases, a common challenge in ALK-positive NSCLC. Comparative studies indicate that ceritinib improves progression-free survival and tumor response rates compared to chemotherapy or other ALK inhibitors in refractory patients, establishing it as a valuable agent in targeted cancer therapy.

Pharmacological Actions

Selective inhibition of anaplastic lymphoma kinase (ALK) receptor tyrosine kinase activity.
Blockade of downstream signaling pathways such as PI3K/AKT, MAPK/ERK, leading to inhibition of cell proliferation.
Induction of apoptosis in ALK-positive tumor cells through disruption of survival signals.
Inhibition of tumor angiogenesis and metastasis.
Activity against crizotinib-resistant ALK mutations in non-small cell lung cancer.
Moderate inhibition of other tyrosine kinases such as ROS1 and IGF-1R.
Potential CNS penetration allowing treatment of brain metastases.
Modulation of cell cycle progression, leading to tumor growth arrest.
Reduction of tumor burden leading to symptom relief in metastatic NSCLC.
Selectivity allows targeted therapy with comparatively less systemic toxicity versus traditional chemotherapies.
Modulation of molecular pathways associated with tumor cell survival and proliferation.
Contributes to increased progression-free survival in ALK-positive NSCLC patients.
Effective in patients intolerant or resistant to prior ALK-targeted therapies.
Demonstrates antineoplastic activity through inhibition of aberrant kinase signaling.
Supports personalized cancer treatment based on genetic tumor profiling.

Therapeutic Or Clinical Uses

Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
Second-line therapy for ALK-positive NSCLC patients who have progressed on or are intolerant to crizotinib.
Management of advanced and metastatic NSCLC with confirmed ALK gene rearrangements.
Targeted therapy based on tumor genetic profiling to improve patient outcomes.
Treatment aiming to reduce tumor size and delay disease progression in ALK-positive lung cancer.
Potential treatment for CNS metastases related to ALK-positive NSCLC.
Improvement of quality of life and symptom control in patients with advanced lung cancer.
Use in patients with limited alternative treatment options due to resistance or intolerance.
Indicated for adults and adolescents meeting ALK-positive tumor criteria.
Component of personalized oncology regimens combining molecular testing and targeted agents.
Therapy aiming to overcome resistance mechanisms to earlier generation ALK inhibitors.
Reducing tumor proliferation and inducing tumor regression by ALK inhibition.
Providing an oral option for systemic treatment of metastatic lung cancer.
Use in combination protocols under clinical trials for expanded oncologic indications.
Palliative treatment option to prolong survival and delay metastatic progression.

Side Or Adverse Effects

Nausea and vomiting, frequently severe and may require antiemetic prophylaxis or treatment.
Diarrhea, which can be persistent and lead to dehydration if untreated.
Abdominal pain and stomach discomfort, sometimes severe.
Elevated liver enzymes and hepatotoxicity presenting as jaundice, dark urine, or right upper quadrant pain.
Hyperglycemia and new onset or worsening of existing diabetes mellitus symptoms.
Fatigue and asthenia impacting patient quality of life.
Weight loss potentially related to gastrointestinal symptoms.
Bradycardia and other cardiac rhythm disturbances including QT prolongation.
Respiratory symptoms including cough, dyspnea, and pneumonitis.
Pancreatitis, characterized by abdominal pain and elevated pancreatic enzymes.
Hypersensitivity reactions including rash, urticaria, and rare anaphylaxis.
Electrolyte imbalances potentially exacerbating cardiac risks.
Risk of severe gastrointestinal toxicity requiring dose interruption or discontinuation.
Potential for serious liver injury necessitating frequent monitoring.
Risk of fetal harm requiring contraception and avoidance during pregnancy.

Precautions

Perform genetic testing to confirm ALK-positivity before initiation to ensure appropriate patient selection.
Monitor liver function tests regularly due to risk of hepatotoxicity.
Assess blood glucose levels prior to and during therapy because of risk of hyperglycemia.
Evaluate cardiac function and monitor for QT interval prolongation, especially in patients with pre-existing heart conditions.
Avoid use in patients with severe hepatic impairment or adjust dose with caution.
Ensure effective contraception methods are used due to teratogenic potential; continue after treatment period as specified.
Monitor electrolyte levels closely and correct imbalances to avoid arrhythmias.
Instruct patients to take Zykadia with food to optimize absorption and reduce gastrointestinal side effects.
Advise patients against grapefruit or grapefruit juice consumption due to CYP3A4 interaction.
Caution in patients with a history of pancreatitis or diabetes mellitus due to potential exacerbation.
Evaluate patients for pre-existing lung disease to mitigate risk of pneumonitis.
Adjust dosing or discontinue therapy if intolerable adverse effects occur below 300 mg daily.
Regularly assess for signs of allergic reactions or hypersensitivity.
Provide thorough counseling on recognizing symptoms of serious side effects requiring immediate medical attention.
Monitor renal function but note minimal impact on dosing in renal impairment.

Warnings

Zykadia can cause serious harm to an unborn baby; effective contraception is mandatory during and after treatment.
Risk of severe hepatotoxicity including fatal cases; monitor liver enzymes frequently.
Potential for life-threatening cardiac adverse events such as QT prolongation and arrhythmias.
Serious pulmonary toxicity including interstitial lung disease and pneumonitis has been reported.
Severe gastrointestinal toxicity including nausea, vomiting, and diarrhea can lead to dehydration and hospitalization.
Risk of severe hyperglycemia requiring urgent management and possible treatment modification.
Fatal pancreatitis has been reported; monitor pancreatic enzymes and symptoms closely.
Avoid concomitant use with strong CYP3A inhibitors or inducers due to potential severe drug interactions.
Discontinue treatment in patients who cannot tolerate the minimum effective dose of 300 mg daily.
Not recommended in pregnancy or breastfeeding due to potential toxicity to fetus or infant.
Monitor for signs of allergic reactions including anaphylaxis; emergency treatment may be necessary.
Avoid use in patients with pre-existing long QT syndrome or significant cardiac conduction abnormalities.
Risk of bleeding complications in patients with liver dysfunction or thrombocytopenia.
May prolong survival in selected patients but improvement in overall survival has not been definitively established.
Use caution in elderly patients who may have multiple comorbidities affecting drug tolerance.

Contraindication

Known hypersensitivity or allergic reaction to ceritinib or any component of Zykadia formulation.
Pregnancy due to teratogenic effects observed in preclinical studies and potential fetal harm.
Breastfeeding women due to potential drug excretion in human milk and risk to nursing infant.
Severe hepatic impairment without ability to monitor and adjust dosing cautiously.
Patients with a history of severe or uncontrolled cardiac arrhythmias including long QT syndrome.
Concomitant use with strong CYP3A inhibitors or inducers that cannot be discontinued or substituted.
Severe gastrointestinal disorders that impair oral medication absorption.
Concomitant use with medications known to prolong QT interval when risks outweigh benefits.
Patients unable to tolerate at least 300 mg per day of ceritinib due to toxicity.
Known electrolyte abnormalities that cannot be corrected prior to treatment initiation.
Patients with active pancreatitis or uncontrolled diabetes mellitus requiring prompt management first.
Individuals with impaired drug metabolism pathways leading to potential drug accumulation.
Children and pediatric patients due to lack of established safety and efficacy data.
Patients with severe infections or compromised immune systems contraindicated until resolution.
Known hypersensitivity to other ALK inhibitors with cross-reactivity concerns.

Drug Interactions

Strong inhibitors or inducers of cytochrome P450 3A (CYP3A) significantly alter ceritinib plasma concentrations.
Grapefruit and grapefruit juice inhibit CYP3A4, increasing ceritinib levels and risk of toxicity; should be avoided.
Co-administration with other drugs that prolong QT interval may increase risk of cardiac arrhythmias.
Co-use with medications that affect electrolyte balance (e.g., diuretics) requires monitoring due to enhanced arrhythmia risk.
Drugs metabolized by CYP3A may have altered plasma levels when given concomitantly with ceritinib.
Use with caution when combined with insulin or oral hypoglycemics due to risk of exacerbated hyperglycemia.
Potential interactions with anticoagulants require monitoring of bleeding parameters.
Concomitant administration with acid-reducing agents may impact absorption and efficacy.
Interactions with other kinase inhibitors may modify toxicity profiles requiring dose adjustment.
Use of herbal supplements metabolized via CYP enzymes necessitates careful evaluation to avoid adverse effects.
Co-administration with immunosuppressants may lead to enhanced immunosuppression or toxicity.
Medication adherence and timing critical when combining ceritinib with other oral chemotherapeutic agents.
Drugs that induce CYP3A may reduce therapeutic levels of ceritinib leading to decreased efficacy.
Periodic monitoring of liver enzymes is recommended when combining ceritinib with hepatotoxic medications.
Potential pharmacodynamic interactions that exacerbate gastrointestinal and metabolic adverse effects.

Preparations Of The Drug

Zykadia is provided as oral capsules containing ceritinib at a strength of 150 mg each.
Capsules designed for once-daily oral administration to ensure patient compliance and steady plasma levels.
Formulation optimized for enhanced absorption when taken with food, specifically high-fat meals.
Supplied in blister packs or bottles with clear labeling and dosage instructions.
Manufactured following stringent pharmaceutical standards ensuring purity and bioavailability.
Packaging includes detailed patient information leaflets for guidance on proper use and safety.
Storage at controlled room temperature, protected from moisture and excessive heat to maintain stability.
Capsules are non-divisible; no evidence supports splitting or crushing due to potential altered pharmacokinetics.
Manufactured by a leading oncology pharmaceutical company specialized in targeted cancer therapies.
Preparation includes solvents and excipients designed to optimize release and minimize gastrointestinal irritation.
Available through specialized oncology pharmacies with distribution controls due to narrow therapeutic indications.
Each lot undergoes quality control testing including potency, purity, and dissolution profile assessment.
Intended for oral use only; no parenteral formulations are currently available.
Patient assistance programs and pricing strategies vary according to manufacturer and healthcare system.
Preparations may be subject to specific handling precautions to avoid accidental exposure to caregivers.